
OKUR Stock Forecast & Price Target
OKUR Analyst Ratings
Bulls say
OnKure Therapeutics is well-positioned in the biopharmaceutical industry with its precision medicine approach and structure-based drug design platform, which sets it apart from its competitors. Its focus on targeting oncogenic PI3Kα, particularly the H1047R mutation, presents a strong clinical and commercial potential, and the company's expansion into other mutations and indications further supplements its growth prospects. With a strong balance sheet and a cash runway into 2029, OnKure has the financial stability to execute its pipeline and achieve its goals.
Bears say
OnKure Therapeutics is trading at a market value of $834M, implying a 12-month price objective of $21 per share. However, the financial outlook for this company is negative due to several factors, including the low probability of approval for their lead asset, OKI-345, delays in advancing pipeline candidates, and potential competition in the market. Additionally, there is a risk of long-term dilution due to the accretion of redeemable convertible preferred stock.
This aggregate rating is based on analysts' research of OnKure Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
OKUR Analyst Forecast & Price Prediction
Start investing in OKUR
Order type
Buy in
Order amount
Est. shares
0 shares